CAC
CLDX icon

Cowen and Company’s Celldex Therapeutics CLDX Stock Holding History

Cowen and Company’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,900
Closed -$78.5K – 77
2024
Q3 		$78.5K Buy
+13,900
New +$530K ﹤0.01% 301

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cowen and Company's CLDX Position: Q4 2024 in Review

Cowen and Company sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 10,700 shares — an estimated $364K sold.

Cowen and Company first reported a position in CLDX in Q2 2021 and held it in 4 quarters. The position peaked at $35.1M in Q3 2021. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • Cowen and Company reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 10,700 Celldex Therapeutics shares in Q4 2024, an estimated $364K.
  • Cowen and Company first reported a position in Celldex Therapeutics in Q2 2021 and held it in 4 quarters.
  • Cowen and Company's Celldex Therapeutics position peaked at $35.1M in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.